CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Cytosorbents Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.96+0.85 (+20.68%)
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
71.5%−1.6 pts over 5 years
Operating margin
-39.8%−14.5 pts over 5 years
Net margin
-22.1%−3.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.1% | +2.2% | -2.0% | +22.7% | |
| Gross profit | +6.4% | +8.5% | -2.4% | +26.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -210.4% | -19.0% | -96.4% | |
| Return on assets | -112.3% | -13.4% | -17.9% | |
| Current ratio | 1.83 | 8.12 | 2.13 | |
| Debt to equity | 3.67 | 0.00 | 2.82 | |
| Net debt to EBITDA | 0.03× | 7.36× | -0.77× | |
| Inventory turnover | 3.9× | 4.6× | 2.6× | |
| Capex to revenue | 1.5% | 1.7% | 0.4% | |
| Diluted shares | 25M | 39M | 62M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cytosorbents generated $90.70M from operations and spent $10.71M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$90.70M
Used
$10.71M
Capital expenditure$10.71M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-22.1%
×Asset turnover0.81×
×Equity multiplier5.38×
=Return on equity, FY2025-96.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -22.1% | 0.81× | 5.38× | -96.4% |
| FY2024 | -58.2% | 0.71× | 2.90× | -119.8% |
| FY2023 | -94.1% | 0.54× | 1.97× | -99.4% |
| FY2022 | -94.6% | 0.45× | 1.56× | -67.0% |
| FY2021 | -56.9% | 0.48× | 1.27× | -34.6% |
| FY2020 | -19.1% | 0.70× | 1.42× | -19.0% |
| FY2019 | -77.2% | 0.81× | 3.03× | -189.3% |
| FY2018 | -76.5% | 0.77× | 2.14× | -126.6% |
| FY2017 | -55.8% | 0.90× | 2.91× | -145.9% |
| FY2016 | -123.5% | 0.91× | 1.87× | -210.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$8.20M
- Cash generatingOperating cash flow above zero-$12.38M
- Return on assets improvedROA up on the prior year-39.1% → -17.3%
- Earnings backed by cashOperating cash flow above net income-$12.38M vs -$8.20M
- Less leverageLong-term debt to assets fell29.5% → 37.7%
- Better liquidityCurrent ratio rose2.20 → 2.13
- No dilutionShare count did not rise54M → 62M
- Gross margin improvedGross margin up on the prior year69.92% → 71.48%
- More efficientAsset turnover rose0.67 → 0.78